Phathom Pharmaceuticals, Inc. Cost of Revenue

Cost of Revenue of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).


Highlights and Quick Summary

  • Cost of Revenue for the quarter ending June 29, 2021 was $131 Thousand (a 4.8% increase compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue increased by 48.86%
  • Annual Cost of Revenue for 2020 was $300 Thousand (a 3650.0% increase from previous year)
  • Twelve month Cost of Revenue ending June 29, 2021 was $427 Thousand (a 14.48% increase compared to previous quarter)
  • Twelve month trailing Cost of Revenue increased by 91.48% year-over-year
Trailing Cost of Revenue for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$427 Thousand $373 Thousand $300 Thousand $223 Thousand
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of Phathom Pharmaceuticals, Inc.

Most recent Cost of Revenueof PHAT including historical data for past 10 years.

Interactive Chart of Cost of Revenue of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.13 $0.13
2020 $0.08 $0.09 $0.08 $0.05 $0.3
2019 $0.01 $0.01

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.